MAP2K7 and familial pancreatic carcinoma: The combination of MEK inhibitor (trametinib) with nab-paclitaxel results in an increased expression of apoptosis-related proteins, including cleaved caspase-3 and cleaved PARP-1, in pancreatic cancer models [140].